secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001193125-24-148076
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Inovio grants performance-based RSUs tied to INO-3107 milestones; stockholders re-elect board
--------------------------------------------------------------------------------

- CEO Shea receives 33,200 target PSUs; CFO Kies and CSO Humeau each receive 8,900 target PSUs.
- Up to 70% of PSUs vest on INO-3107 milestones (FDA approval, launch, market share, sales) by 2025-2027.
- Remaining 30% vest on relative TSR vs. Russell 2000 Biotech index June 2024-Dec 2027 (50%-150% of target).
- Stockholders ratified Ernst & Young as auditor (11.1M for) and approved non-binding say-on-pay (3.0M for).
- All eight director nominees elected with votes ranging 3.1M-3.8M for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312524148076/0001193125-24-148076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312524148076/d597714d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-148076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer